Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

The high court preserved a key part of the Affordable Care Act requiring private insurers cover a range of preventive ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...